Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial (vol 18, pg 1493, 2017)

被引：0
|
作者：
Tawbi, H. A.
Burgess, M.
Bolejack, V
机构：
来源：
LANCET ONCOLOGY | 2017年 / 18卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E711 / E711
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial (vol 18, pg 1493, 2017)
    Tawbi, H. A.
    Burgess, M.
    Bolejack, V
    LANCET ONCOLOGY, 2018, 19 (01): : E8 - E8
  • [2] Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
    Tawbi, Hussein A.
    Burgess, Melissa
    Bolejack, Vanessa
    Van Tine, Brian A.
    Schuetze, Scott M.
    Hu, James
    D'Angelo, Sandra
    Attia, Steven
    Riedel, Richard F.
    Priebat, Dennis A.
    Movva, Sujana
    Davis, Lara E.
    Okuno, Scott H.
    Reed, Damon R.
    Crowley, John
    Butterfield, Lisa H.
    Salazar, Ruth
    Rodriguez-Canales, Jaime
    Lazar, Alexander J.
    Wistuba, Ignacio I.
    Baker, Laurence H.
    Maki, Robert G.
    Reinke, Denise
    Patel, Shreyaskumar
    LANCET ONCOLOGY, 2017, 18 (11): : 1493 - 1501
  • [3] Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Schwartz, Gary K.
    Tap, William D.
    Qin, Li-Xuan
    Livingston, Michael B.
    Undevia, Samir D.
    Chmielowski, Bartosz
    Agulnik, Mark
    Schuetze, Scott M.
    Reed, Damon R.
    Okuno, Scott H.
    Ludwig, Joseph A.
    Keedy, Vicki
    Rietschel, Petra
    Kraft, Andrew S.
    Adkins, Douglas
    Van Tine, Brian A.
    Brockstein, Bruce
    Yim, Vincent
    Bitas, Christiana
    Abdullah, Abdul
    Antonescu, Cristina R.
    Condy, Mercedes
    Dickson, Mark A.
    Vasudeva, Shyamprasad Deraje
    Ho, Alan L.
    Doyle, L. Austin
    Chen, Helen X.
    Maki, Robert G.
    LANCET ONCOLOGY, 2013, 14 (04): : 371 - 382
  • [4] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Kjetil Boye
    Alessandra Longhi
    Tormod Guren
    Susanne Lorenz
    Stine Næss
    Michela Pierini
    Ingeborg Taksdal
    Ingvild Lobmaier
    Marilena Cesari
    Anna Paioli
    Ayca M. Løndalen
    Elisabetta Setola
    Ivar Hompland
    Leonardo A. Meza-Zepeda
    Kirsten Sundby Hall
    Emanuela Palmerini
    Cancer Immunology, Immunotherapy, 2021, 70 : 2617 - 2624
  • [5] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Boye, Kjetil
    Longhi, Alessandra
    Guren, Tormod
    Lorenz, Susanne
    Naess, Stine
    Pierini, Michela
    Taksdal, Ingeborg
    Lobmaier, Ingvild
    Cesari, Marilena
    Paioli, Anna
    Londalen, Ayca M.
    Setola, Elisabetta
    Hompland, Ivar
    Meza-Zepeda, Leonardo A.
    Hall, Kirsten Sundby
    Palmerini, Emanuela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
  • [6] Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
    Wang, Zhi-ming
    Zhuang, Rong-yuan
    Guo, Xi
    Zhang, Chen-lu
    You, Yang
    Chen, Li-sha
    Liu, Wen-shuai
    Zhang, Yong
    Luo, Rong-kui
    Hou, Ying-yong
    Lu, Wei-qi
    Zhou, Yu-hong
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5290 - 5296
  • [7] First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
    Li, Tao
    Dong, Ying
    Wei, Yongzhong
    Wang, Shoufeng
    Liu, Yunxia
    Chen, Jia
    Xiong, Wenhua
    Lin, Nong
    Huang, Xin
    Liu, Meng
    Yan, Xiaobo
    Ye, Zhaoming
    Li, Binghao
    CLINICAL CANCER RESEARCH, 2024, 30 (19) : 4310 - 4317
  • [8] Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006) a multicentre, open-label, single-arm, phase 2 trial
    Xu, Bushu
    Pan, Qiuzhong
    Pan, Hua
    Li, Haomiao
    Li, Xianan
    Chen, Jing
    Pang, Danmei
    Zhang, Baoqing
    Weng, Desheng
    Peng, Ruiqing
    Fang, Meiyu
    Zhang, Xing
    ECLINICALMEDICINE, 2023, 64
  • [9] Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial (vol 18, pg 1089, 2017)
    Tap, W. D.
    Papai, Z.
    Van Tine, B. A.
    LANCET ONCOLOGY, 2018, 19 (02): : E78 - E78
  • [10] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    Makker, Vicky
    Rasco, Drew
    Vogelzang, Nicholas J.
    Brose, Marcia S.
    Cohn, Allen L.
    Mier, James
    Di Simone, Christopher
    Hyman, David M.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Schmidt, Emmett V.
    Guo, Matthew
    Sachdev, Pallavi
    Shumaker, Robert
    Aghajanian, Carol
    Taylor, Matthew
    LANCET ONCOLOGY, 2019, 20 (05): : 711 - 718
12345